Completed PHASE2 INTERVENTIONAL 5-arm NCT07020884

A Study of ZT002 Injection With Subjects With Overweight or Obesity

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of ZT002 Injection in Subjects With Overweight or Obesity

Sponsor: Beijing QL Biopharmaceutical Co.,Ltd

Conditions Overweight or Obesity

Interventions ZT002 Injection ZT002 Placebo

Updated 3 times since 2025 Last updated: Dec 3, 2025 Started: Aug 14, 2024 Primary completion: May 7, 2025 Completion: May 29, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07020884, this PHASE2 trial focuses on Overweight or Obesity and remains completed. Sponsored by Beijing QL Biopharmaceutical Co.,Ltd, it has been updated 3 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Sep 2025 — Jan 2026 [monthly]

Active Not Recruiting PHASE2
Jul 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE2

First recorded

Aug 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing QL Biopharmaceutical Co.,Ltd

Data source: Beijing QL Biopharmaceutical Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Handan, China , Harbin, China , Jinan, China , Langfang, China , Luoyang, China , Nanjing, China , Nanyang, China , Panjin, China , Qinhuangdao, China and 4 more locations